Versartis Inc. started a Phase I clinical trial of a treatment for growth hormone deficiency.
The Mountain View company is testing the safety and efficacy of VRS-317, a once monthly form of recombinant human growth hormone meant to be easier to use than current daily treatments.
A Phase I trial is typically done with just a handful of patients to make sure a treatment is safe, although data is also collected on how well a treatment works. This test will use about 50 patients in the United States and Europe.
Jeffrey Cleland, who started Versartis, is its CEO.